$8.15
4.57%
Nasdaq, Nov 17, 03:59 pm EST. Closed.
ISIN
US08205P1003
Symbol
BNTC

Benitec Biopharma Inc Stock price

$8.15
-0.21 2.51% 1M
-2.74 25.16% 6M
-5.32 39.50% YTD
-5.38 39.76% 1Y
+4.72 137.61% 3Y
-49.82 85.94% 5Y
-254.88 96.90% 10Y
-201.85 96.12% 20Y
Nasdaq, Closing price Tue, Nov 17 2026
-0.39 4.57%
ISIN
US08205P1003
Symbol
BNTC
Industry

Is Benitec Biopharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,087 stocks worldwide.

Key metrics

Basic
Market capitalization
$294.4m
Enterprise Value
$114.4m
Net debt
positive
Cash
$180.0m
Shares outstanding
34.4m
Valuation
P/E
-
P/S | estimate
- | -
EV/Sales | estimate
- | -
EV/FCF | ex SBC
negative | negative
P/B
1.7
Dividends
DPS
$0.00
Yield 1Y | 5Y
0.0% | 0.0%
Growth 1Y | 5Y
- | -
Payout 1Y | 3Y
- | -
Increased
0 Years
Financials
Revenue | estimate
- | $0.0
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow | ex SBC
$-16.6m | $-43.0m
Growth
Revenue | estimate
- | -
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow
29.6%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
Financial Health
Equity Ratio
-
Return on Equity
-
ROCE
-
ROIC
-
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$26.4m | -
SBC as % of FCF
-
SBC Growth 1Y
51.5%
Share Count Growth 1Y
31.1%
Shareholder Yield
-31.1%
More
EPS
-
FCF per Share
$-0.5
Short interest
15.2%
Employees
19
Rev per Employee
-

Benitec Biopharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Benitec Biopharma Inc forecast:

13x Buy
93%
1x Hold
7%

Analyst Opinions

14 Analysts have issued a Benitec Biopharma Inc forecast:

Buy
93%
Hold
7%

Benitec Biopharma Inc Events

Past Events
NOV
12
Q1 2027 Earnings Call
5 days ago

Financial data from Benitec Biopharma Inc

Mar '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 36 36
150% 150%
-
- Research and Development Expense 30 30
91% 91%
-
-54 -54
80% 80%
-
- Depreciation and Amortization 0.06 0.06
57% 57%
-
EBIT (Operating Income) EBIT -54 -54
79% 79%
-
Net Profit -49 -49
80% 80%
-

In millions USD.

Don't miss a Thing! We will send you all news about Benitec Biopharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Benitec Biopharma Inc Stock News

Neutral
GlobeNewsWire
●
5 days ago
Positive interim clinical results from the ongoing BB-301 Phase 1b/2a study for dysphagic patients with Oculopharyngeal Muscular Dystrophy (OPMD), presented as a late-breaking poster at the European Society of Gene and Cell Therapy (ESGCT) Annual Congress showed a 100% responder rate across all Cohort 1 (low dose) and Cohort 2 (high dose) patients BB-301 pivotal study design to be finalized in ...
Neutral
GlobeNewsWire
●
5 days ago
Positive interim clinical results from the ongoing BB-301 Phase 1b/2a study for dysphagic patients with Oculopharyngeal Muscular Dystrophy (OPMD), presented as a late-breaking poster at the European Society of Gene and Cell Therapy (ESGCT) Annual Congress showed a 100% responder rate across all Cohort 1 (low dose) and Cohort 2 (high dose) patients The BB-301 pivotal trial remains on track to be...
Neutral
GlobeNewsWire
●
21 days ago
- Both low dose and high dose BB-301 continue to drive robust improvements in swallowing function for dysphagic Patients with Oculopharyngeal Muscular Dystrophy (OPMD) - 100% of Patients treated with BB-301 across both doses are formal Responders to therapy - Interim clinical results for Patients treated with high dose BB-301 demonstrate greater relative improvements at the 3-month post-treatme...
More Benitec Biopharma Inc News

Company Profile

Benitec Biopharma, Inc. is a development-stage biotechnology company, which focuses on the advancement of novel genetic medicines. The firms proprietary platforms includes DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitates sustained silencing of disease-causing genes following a single administration. It is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy, and Chronic Hepatitis B. The company was founded on April 13, 2020 and is headquartered in Hayward, CA.

Head office United States
CEO Dr. Banks
Employees 19
Founded 2019
Website www.benitec.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today